---
title: "Salubris: SAL0139 drug clinical trial application accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256120721.md"
description: "According to the Zhitong Finance APP, Salubris announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the independently developed innovative small molecule drug SAL0139 (project code: SAL0139) has been accepted. The announcement shows that SAL0139 is a small molecule drug with independent intellectual property rights owned by the company, and the application submitted this time is for the clinical trial of SAL0139 for the treatment of hyperlipidemia"
datetime: "2025-09-05T11:24:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256120721.md)
  - [en](https://longbridge.com/en/news/256120721.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256120721.md)
generator: "portal-rs"
---

# Salubris: SAL0139 drug clinical trial application accepted

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0139 (project code: SAL0139) has been accepted. The announcement shows that SAL0139 is a small molecule drug with independent intellectual property rights held by the company, and the application submitted this time is for the clinical trial of SAL0139 for the treatment of hyperlipidemia

### Related Stocks

- [002294.CN](https://longbridge.com/en/quote/002294.CN.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**